share_log

Aurora Cannabis | 6-K: Report of foreign private issuer (related to financial reporting)

Aurora Cannabis | 6-K: Report of foreign private issuer (related to financial reporting)

極光大麻 | 6-K：外國發行人報告（業績相關）
美股SEC公告 ·  2024/08/07 07:21

Moomoo AI 已提取核心訊息

Aurora Cannabis Inc. reported strong Q1 FY2025 results, delivering positive free cash flow of $6.5 million and a 12% year-over-year increase in total net revenue to $83.4 million. The company's global medical cannabis segment achieved record net revenue of $47.2 million, up 13% from the prior year.Adjusted EBITDA rose 87% to $4.9 million, while adjusted gross margin before fair value adjustments on total net revenue was 43%. The company ended the quarter with a debt-free cannabis business and a cash position of approximately $182 million. Aurora's plant propagation business, Bevo, contributed $23.1 million in net revenue, a 16% increase year-over-year.For Q2 FY2025, Aurora expects continued strong net revenue and adjusted gross margins across its cannabis business, supported by growth in Europe and Australia. The company anticipates positive adjusted EBITDA to continue, while free cash flow may be impacted by significant annual and one-time cash payments typically occurring in Q2.
Aurora Cannabis Inc. reported strong Q1 FY2025 results, delivering positive free cash flow of $6.5 million and a 12% year-over-year increase in total net revenue to $83.4 million. The company's global medical cannabis segment achieved record net revenue of $47.2 million, up 13% from the prior year.Adjusted EBITDA rose 87% to $4.9 million, while adjusted gross margin before fair value adjustments on total net revenue was 43%. The company ended the quarter with a debt-free cannabis business and a cash position of approximately $182 million. Aurora's plant propagation business, Bevo, contributed $23.1 million in net revenue, a 16% increase year-over-year.For Q2 FY2025, Aurora expects continued strong net revenue and adjusted gross margins across its cannabis business, supported by growth in Europe and Australia. The company anticipates positive adjusted EBITDA to continue, while free cash flow may be impacted by significant annual and one-time cash payments typically occurring in Q2.
Aurora Cannabis Inc. 報告了強勁的2025財年第一季度業績，實現了650萬美元的自由現金流，並且總營業收入同比增長12%，達到8340萬美元。公司的全球醫療大麻部門實現了創紀錄的4720萬美元淨營業收入，比去年增長了13%。調整後的EBITDA增長了87%，達到490萬美元，而總營業收入在公允價值調整之前的調整毛利率爲43%。公司在季度末結束時擁有無債務的大麻業務，現金餘額約爲18200萬美元。Aurora的植物繁殖業務Bevo貢獻了2310萬美元的淨營業收入，同比增長16%。對於2025財年第二季度，Aurora預計其大麻業務將持續實現強勁的淨營業收入和調整後的毛利率，這得益於歐洲和澳洲的增長。公司預期調整後的EBITDA將繼續爲正，而自由現金流可能會受到通常在第二季度發生的重大年度和一次性現金支付的影響。
Aurora Cannabis Inc. 報告了強勁的2025財年第一季度業績，實現了650萬美元的自由現金流，並且總營業收入同比增長12%，達到8340萬美元。公司的全球醫療大麻部門實現了創紀錄的4720萬美元淨營業收入，比去年增長了13%。調整後的EBITDA增長了87%，達到490萬美元，而總營業收入在公允價值調整之前的調整毛利率爲43%。公司在季度末結束時擁有無債務的大麻業務，現金餘額約爲18200萬美元。Aurora的植物繁殖業務Bevo貢獻了2310萬美元的淨營業收入，同比增長16%。對於2025財年第二季度，Aurora預計其大麻業務將持續實現強勁的淨營業收入和調整後的毛利率，這得益於歐洲和澳洲的增長。公司預期調整後的EBITDA將繼續爲正，而自由現金流可能會受到通常在第二季度發生的重大年度和一次性現金支付的影響。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間